Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Plavix Falsely Marketed as Superior Version of Aspirin

Filed March 28th, 2013 edlieber1

A group of Korean researchers found that extra-extended dual platelet therapy with Plavix and aspirin is no better than aspirin alone in patients who have a drug-eluting stent.

In a study known as the DES-LATE trial, researchers found that dual therapy with Bristol-Myers Squibb and Sanofi-Aventis’s Plavix and aspirin also carried a higher risk of bleeding compared with aspirin-only therapy. This is just the latest data in a growing body of research that shows how adding Plavix to standard aspirin therapy offers few additional benefits, and can in fact be dangerous, publichealthwatchdog.com said. The research supports anyone who has filed a lawsuit over the blood thinning drug, and helps confirm that Plavix is an unnecessary treatment falsely marketed as a superior version of aspirin.

The researchers found that the risks of heart attack, stroke and cardiac death were the same whether patients were taking aspirin and Plavix for 36 months or longer, or switched to aspirin alone after one year, publichealthwatchdog.com said. Cheol Whan Lee, MD, and his colleagues presented the study at the American College of Cardiology, saying that there was no other endpoint favoring dual therapy.

Bristol-Myers Squibb and Sanofi-Aventis, the manufacturers, are facing a host of lawsuits over injuries alleged to be from the blood thinner, publichealthwatchdog.com said. They are also under investigation by the U.S. Department of Justice over claims they made about Plavix to the U.S. Food and Drug Administration (FDA) regarding the responses of individuals to the drug. In March 2010, the FDA updated the Plavix label to include a black box warning stating that close to 3 percent of the population is unable to metabolize the blood thinner.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!